Recently,
Acxiom Corporation
(
ACXM
) declared the winning of a multi-year contract for providing
end-to-end services. The order came from New Jersey's biggest
health insurance organization, Horizon Healthcare Services,
Inc.
Acxiom shall be providing a wide range of its advanced marketing
and analytic services in order to develop personalized and
interconnected marketing program systems for Horizon, catering to
the betterment of the latter's vast health clientele. These
services shall include InfoBase, Universal Patient Link (
UPL
), Acxiom Consumer Insights and proficient consultancy services for
Horizon's present and potential customers.
It is the global reputation along with expertise in providing
end-to-end solutions that has made the company achieve this massive
contract. Management had always retained its keen interest in
technological advancements and come up with innovation-centric
strategies in order to better serve its customers with
state-of-the-art solutions.
On Feb 16, 2012, ThinkVine added Acxiom to its Value Added
Reseller (
VAR
) program. According to this agreement, Acxiom shall incorporate
ThinkVine's ThinkAhead technology platform with the intent of
ameliorating sales, achieving flexibility in marketing management
and yielding better returns on its marketing investments. Such
moves are encouraging considering the uncertainty still prevailing
in the world economic scenario.
However, Acxiom should be ever vigilant on performances of its
competitors in the industry. Such ominous players include
Camelot Information Systems Inc.
(
CIS
),
Costar Group, Inc.
(
CSGP
) and
Computer Task Group Inc.
(
CTGX
).
The company currently retains a Zacks #3 Rank, which translates
into a short-term 'Hold' rating. We also maintain a long-term
'Neutral' recommendation on the stock.
ACXIOM CORP (
ACXM
): Free Stock Analysis Report
CAMELOT INF-ADS (
CIS
): Free Stock Analysis Report
COSTAR GRP INC (
CSGP
): Free Stock Analysis Report
COMP TASK (CTGX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment
Research